Show simple item record

dc.creatorTostanoski, Lisa H.
dc.creatorWegmann, Frank
dc.creatorMartinot, Amanda J.
dc.creatorLoos, Carolin
dc.creatorMcMahan, Katherine
dc.creatorMercado, Noe B.
dc.creatorYu, Jingyou
dc.creatorChan, Chi N.
dc.creatorBondoc, Stephen
dc.creatorStarke, Carly E.
dc.creatorNekorchuk, Michael
dc.creatorBusman-Sahay, Kathleen
dc.creatorPiedra-Mora, Cesar
dc.creatorWrijil, Linda M.
dc.creatorDucat, Sarah
dc.creatorCusters, Jerome
dc.creatorAtyeo, Caroline
dc.creatorFischinger, Stephanie
dc.creatorBurke, John S.
dc.creatorFeldman, Jared
dc.creatorHauser, Blake M.
dc.creatorCaradonna, Timothy M.
dc.creatorBondzie, Esther A.
dc.creatorDagotto, Gabriel
dc.creatorJacob-Dolan, Catherine
dc.creatorLin, Zijin
dc.creatorMahrokhian, Shant H.
dc.creatorNampanya, Felix
dc.creatorNityanandam, Ramya
dc.creatorPessaint, Laurent
dc.creatorPorto, Maciel
dc.creatorAli, Vaneesha
dc.creatorBenetiene, Dalia
dc.creatorTevi, Komlan
dc.creatorAndersen, Hanne
dc.creatorLewis, Mark G.
dc.creatorSchmidt, Aaron G.
dc.creatorLauffenburger, Douglas A.
dc.creatorAlter, Galit
dc.creatorEstes, Jacob D.
dc.creatorSchuitemaker, Hanneke
dc.creatorZahn, Roland
dc.creatorBarouch , Dan H.
dc.date.accessioned2020-09-18T14:17:27Z
dc.date.available2020-09-18T14:17:27Z
dc.date.created2020
dc.identifier.issn1546-170Xspa
dc.identifier.otherhttps://doi.org/10.1038/s41591-020-1070-6spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/13448
dc.description.abstractCoronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death1–4. Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters5–7 and nonhuman primates8–10 have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates11–13. Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis.spa
dc.format.extent23 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherNature medicinespa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectAd26 vaccinespa
dc.subjectSARS-CoV-2spa
dc.subjectClinical diseasespa
dc.titleAd26 vaccine protects against SARS-CoV-2 severe clinical disease in hamstersspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1038/s41591-020-1070-6spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record